Osmotica Pharmaceutical
- Company typePublic
- Founded1980
- HeadquartersMarietta, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Osmotica Pharmaceutical firmographics
Firmographics- Name
- Osmotica Pharmaceutical
- Legal name
- Osmotica Pharmaceuticals plc
- Website
- https://osmotica.com
- Company type
- Public
- Founded year
- 1980
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Osmotica Pharmaceutical industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Osmotica Pharmaceutical is headquartered
LocationHeadquarters
- HQ city
- Marietta
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Osmotica Pharmaceutical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: The company generates revenue through the sale of pharmaceutical products including five promoted products and approximately 35 non-promoted products. Promoted products include methylphenidate HCl ER tablets, Lorzone, ConZip, Divigel, and OB Complete. Non-promoted products include methylphenidate HCl ER tablets, venlafaxine HCl ER tablets, and prescription and non-prescription dietary supplements.
- CDMO Services: Contract Development and Manufacturing Organization (CDMO) providing full service from development through commercial manufacturing with full analytical support. Services include FDA inspected facility with technical expertise in extended and modified release technologies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Prescription pharmaceutical products sold through healthcare providers and pharmacies |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Osmotica Pharmaceutical product offering
Product offeringCore offering
Osmotica Pharmaceutical is a fully-integrated specialty pharmaceutical company that develops, manufactures, and commercializes prescription pharmaceutical products—primarily in specialty neurology and women's health—using its proprietary Osmodex® osmotic drug delivery system. The company also operates a CDMO (Contract Development and Manufacturing Organization) business providing full-service development through commercial manufacturing for complex controlled and modified release formulations.
Product overview
Osmotica Pharmaceuticals is a fully-integrated biopharmaceutical company and CDMO (Contract Development and Manufacturing Organization) offering a diversified portfolio of five promoted products and approximately 35 non-promoted products. The company's core proprietary technology is the Osmodex® drug delivery system, which enables controlled and modified drug release formulations. Promoted products include Upneeq® for acquired ptosis, OSMOLEX ER™ for Parkinson's disease, Methylphenidate HCl ER 72 mg, Lorzone®, ConZip®, Divigel®, and OB Complete®. The pipeline includes Arbaclofen ER and RVL-1201 in Phase III clinical trials. Products are developed using Osmodex® technology which supports immediate release, controlled release, delayed release, and extended release formulations.
Differentiator
Problem solved
Functional benefit
Products and services
- Upneeq® Prescription treatment for acquired ptosis (drooping eyelid); the first and only FDA-approved prescription eyedrop for this condition.
- OSMOLEX ER™ (amantadine) Extended-release tablets for the treatment of Parkinson's Disease and Drug-Induced Extrapyramidal Reactions in adults.
- Methylphenidate HCl ER 72 mg Tablets (M-72) Extended-release methylphenidate tablets for ADHD treatment, incorporating the proprietary Osmodex® drug delivery system.
- Lorzone® (chlorzoxazone USP)
- ConZip® (tramadol hydrochloride)
- Divigel® (estradiol gel) 0.1%
- OB Complete®
- CDMO Services
Companies that use Osmotica Pharmaceutical
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Osmotica Pharmaceutical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Osmotica Pharmaceutical partnerships and signals
Strategic signalScale indicators4 records
Recent moves9 records
Expansion highlights6 records
Osmotica Pharmaceutical competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Osmotica Pharmaceutical social profiles
Digital presenceOsmotica Pharmaceutical compliance and trust
Trust signalCompliance2 records
Osmotica Pharmaceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Osmotica Pharmaceutical leadership team
Management profileNumber of profiles
Profiles14 records
Osmotica Pharmaceutical subsidiaries and ownership
Company hierarchySubsidiaries2 records
Osmotica Pharmaceutical funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Osmotica Pharmaceutical M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Osmotica Pharmaceutical
What does Osmotica Pharmaceutical do?
Osmotica Pharmaceutical is a fully-integrated specialty pharmaceutical company that develops, manufactures, and commercializes prescription pharmaceutical products—primarily in specialty neurology and women's health—using its proprietary Osmodex® osmotic drug delivery system. The company also operates a CDMO (Contract Development and Manufacturing Organization) business providing full-service development through commercial manufacturing for complex controlled and modified release formulations.
Is Osmotica Pharmaceutical a public or private company?
Osmotica Pharmaceutical is a public company. It is classified as corporate owned and is currently acquired.
When was Osmotica Pharmaceutical founded?
Osmotica Pharmaceutical was founded in 1980. It employs 251 to 500 people.
Where is Osmotica Pharmaceutical based?
Osmotica Pharmaceutical is headquartered in Marietta, United States, in the North America region.
How does Osmotica Pharmaceutical make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are CDMO Services.
Does Osmotica Pharmaceutical have an API?
No public API is recorded for Osmotica Pharmaceutical.
What industry is Osmotica Pharmaceutical in?
Osmotica Pharmaceutical's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.